Microglial VEGF receptor response is an integral chemotactic component in Alzheimer's disease pathology. - AlzForum Alzheimer Research Paper of the Week


	Current Papers
	ARF Recommends
	Milestone Papers
	Search All Papers
	Search Comments


	Research News
	Drug News
	Conference News


	AD Hypotheses
		AlzSWAN
		Current Hypotheses
		Hypothesis Factory
	Forums
		Live Discussions
		Virtual Conferences
		Interviews
	Enabling Technologies
		Workshops
		Research Tools
	Compendia
		AlzGene
		AlzRisk
		Antibodies
		Biomarkers
		Mutations
		Protocols
		Research Models
		Video Gallery
	Resources
		Bulletin Boards
		Conference Calendar
		Grants
		Jobs


	Overview
	Diagnosis/Genetics
	Research
	News
	Profiles
	Clinics


	Companies
	Tutorial
	Drugs in Clinical Trials


	About Alzheimer's
		FAQs
	Diagnosis
		Clinical Guidelines
		Tests
		Brain Banks
	Treatment
		Drugs and Therapies
	Caregiving
		Patient Care
		Support Directory
		AD Experiences


	Member Directory
	Researcher Profiles
	Institutes and Labs


	Mission
	ARF Team
	ARF Awards
	Advisory Board
	Sponsors
	Partnerships
	Fan Mail
	Support Us

Home: Papers of the Week

Annotation

	Ryu JK, Cho T, Choi HB, Wang YT, McLarnon JG. Microglial VEGF receptor response is an integral chemotactic component in Alzheimer's disease pathology. J Neurosci. 2009 Jan 7;29(1):3-13. PubMed Abstract

	Comments on Paper and Primary News

	Comment by: Ben Barres, ARF Advisor
	Submitted 12 January 2009 \| Permalink	Posted 12 January 2009
	My comment is that they would need to do a conditional knockout of flt-1 in microglia to make the case more convincing. Flt-1 is well documented to be endothelial specific, and when I look at our gene profiles of various purified brain cell types (neurons, astrocytes, oligodendrocytes, endothelial cells, and microglia—including activated microglia), the only ones that express flt-1 are endothelial cells. View all comments by Ben Barres

Submit a Comment on this Paper

Cast your vote and/or make a comment on this paper.

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name
*Last Name
Country or Territory:
*Login Email Address
*Password	Minimum of 8 characters
*Confirm Password
Stay signed in?

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:

*Enter the verification code you see in the picture below:

This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:	Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.

REAGENTS/MATERIAL:
Primary antibodies used in this study include
Immunofluorescence, human brain: rabbit anti-human Flt-1 (R&D Systems); rabbit anti-VEGF (Santa Cruz Biotechnology); monoclonal mouse anti-HLA-DR (TAL.1B5) (DakoCytomation) and monoclonal mouse anti-β-amyloid (6F/3D) (DakoCytomation)
Immunocytochemistry, cell purity: anti-CD11b (American Type Culture Collection); anti-(HLA-DR) (CN Pharmaceuticals) and anti-CD68 (1:1000; Accurate Chemical and Scientific).
Immunohistochemistry, rat brain: anti-Flt-1 (Santa Cruz Biotechnology); rabbit anti-Iba-1, a marker for microglia (Wako Chemicals); anti-GFAP (Sigma-Aldrich); monoclonal mouse anti-NeuN (Millipore Bioscience) and monoclonal goat anti-CR3R (OX-42) (Serotec)